Register Login

AGOMAB THERAPEUTICS NV (AGMB)

SymbolAGMB
NameAGOMAB THERAPEUTICS NV
SectorHEALTH CARE
RegionEurope
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
AddressPOSTHOFLEI 1/6, ANTWERPEN, 2600, Belgium
Telephone+32 3318 9170
Fax—
Email—
Websitewww.agomab.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0002020932
Description

AgomAb Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Our product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches.

Additional info from NASDAQ:
AgomAb Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Our product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches.

2026-06-23 20:05

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease

Read more
2026-05-27 09:00

Agomab Announces Results of Annual General Meeting

Read more
2026-05-15 17:45

New Form SCHEDULE 13G - Agomab Therapeutics NV <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001104659-26-062718 <b>Size:</b> 12 KB

Read more
2026-05-15 14:15

New Form SCHEDULE 13G - Agomab Therapeutics NV <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001172661-26-002216 <b>Size:</b> 10 KB

Read more
2026-05-14 11:30

Agomab to Participate in Upcoming Conferences

Read more
2026-05-06 07:08

New Form SCHEDULE 13G - Agomab Therapeutics NV <b>Filed:</b> 2026-05-06 <b>AccNo:</b> 0001193125-26-207455 <b>Size:</b> 7 KB

Read more
2026-04-24 20:22

AGOMAB THERAPEUTICS NV (AGMB) Files Form 6-K

Read more
2026-04-23 22:14

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Read more
2026-04-16 10:15

New Form SCHEDULE 13G - Agomab Therapeutics NV <b>Filed:</b> 2026-04-16 <b>AccNo:</b> 0001213900-26-044365 <b>Size:</b> 20 KB

Read more
2026-03-26 11:00

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Read more